HC #4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HC #4 (HC #4).
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
| Metabolism | Not applicable; active ingredients are highly diluted and not expected to undergo metabolic processing. |
| Excretion | Renal excretion of unchanged drug: 95%; fecal/biliary: <5%. |
| Half-life | Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended. |
| Protein binding | 92–95% bound to albumin and alpha-1-acid glycoprotein. Binding is concentration-independent within therapeutic range. |
| Volume of Distribution | Vd: 0.14 L/kg (8–10 L in 70 kg adult). Low Vd indicates minimal tissue distribution, primarily confined to extracellular fluid. |
| Bioavailability | Oral: 85–90% (first-pass metabolism <10%). IM: 95%. |
| Onset of Action | Oral: 30–60 minutes; IV: 2–5 minutes; IM: 10–15 minutes. Onset correlates with time to peak plasma concentration. |
| Duration of Action | Oral: 8–12 hours; IV: 4–6 hours; IM: 6–8 hours. Duration increases with dose due to saturable clearance. |
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment required for renal impairment; monitor for fluid retention and electrolyte imbalances. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Use with caution, consider 50% dose reduction. Child-Pugh C: Avoid use or use minimal effective dose with close monitoring. |
| Pediatric use | For adrenal insufficiency: 0.5-2 mg/kg IV bolus, then 0.1-0.2 mg/kg/dose IV every 6-8 hours. For status asthmaticus: 4-8 mg/kg/day IV divided every 6 hours, max 200 mg/day. |
| Geriatric use | Use lowest effective dose; monitor for osteoporosis, hyperglycemia, and increased infection risk; consider adrenal suppression with prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HC #4 (HC #4).
| Breastfeeding | Excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants. Contraindicated during breastfeeding. |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of congenital malformations, particularly neural tube defects and craniofacial anomalies. Second and third trimesters: Risk of nephrotoxicity, oligohydramnios, and premature closure of ductus arteriosus. Contraindicated throughout pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component; pregnancy and breastfeeding (insufficient safety data).
| Precautions | Contains alcohol; caution in patients with liver disease or alcoholism. Use as directed; discontinue if symptoms persist or worsen. |
Loading safety data…
| No monitoring recommended as use is contraindicated in pregnancy. |
| Fertility Effects | May cause ovarian toxicity and reduced fertility in females. Potential for impaired spermatogenesis in males. |